Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cullinan Therapeutics Inc (CGEM)

Cullinan Therapeutics Inc (CGEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 684,691
  • Shares Outstanding, K 59,076
  • Annual Sales, $ 0 K
  • Annual Income, $ -167,380 K
  • EBIT $ -241 M
  • EBITDA $ -241 M
  • 60-Month Beta -0.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.53

Options Overview Details

View History
  • Implied Volatility 314.83% (+14.62%)
  • Historical Volatility 57.29%
  • IV Percentile 88%
  • IV Rank 37.48%
  • IV High 740.76% on 09/19/25
  • IV Low 59.52% on 08/18/25
  • Expected Move (DTE 6) 1.91 (16.50%)
  • Put/Call Vol Ratio 0.75
  • Today's Volume 14
  • Volume Avg (30-Day) 184
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 5,578
  • Open Int (30-Day) 4,994
  • Expected Range 9.68 to 13.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.80
  • Number of Estimates 7
  • High Estimate -0.54
  • Low Estimate -0.99
  • Prior Year -0.73
  • Growth Rate Est. (year over year) -9.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.45 +10.91%
on 01/20/26
13.43 -13.70%
on 02/03/26
+0.86 (+8.01%)
since 01/13/26
3-Month
7.93 +46.15%
on 11/14/25
13.43 -13.70%
on 02/03/26
+3.32 (+40.15%)
since 11/13/25
52-Week
5.68 +104.05%
on 10/03/25
13.43 -13.70%
on 02/03/26
+2.00 (+20.86%)
since 02/13/25

Most Recent Stories

More News
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026

CAMBRIDGE, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class,...

CGEM : 11.59 (-0.86%)
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones

Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended...

CGEM : 11.59 (-0.86%)
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting

CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML ...

CGEM : 11.59 (-0.86%)
Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patients CAMBRIDGE, Mass., Dec. 01,...

CGEM : 11.59 (-0.86%)
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

PRINCETON, N.J. and TOKYO and CAMBRIDGE, Mass. , Nov. 20, 2025 /PRNewswire/ -- Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced...

CGEM : 11.59 (-0.86%)
Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting

CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company accelerating potential high-impact therapies in autoimmune...

CGEM : 11.59 (-0.86%)
Cullinan Therapeutics: Q3 Earnings Snapshot

Cullinan Therapeutics: Q3 Earnings Snapshot

CGEM : 11.59 (-0.86%)
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Promising Phase 1 clinical data for CLN-049, a FLT3xCD3 bispecific T cell engager, demonstrating ~30% CRc rate in heavily pretreated, all-comer population of patients with relapsed/refractory AML to be...

CGEM : 11.59 (-0.86%)
Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting

CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, regardless of FLT3 mutational status ~30% CRc rate...

CGEM : 11.59 (-0.86%)
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM),...

CGEM : 11.59 (-0.86%)

Business Summary

Cullinan Therapeutics Inc. is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. The company's product pipeline consists CLN-978. Cullinan Therapeutics Inc., formerly known as Cullinan Oncology Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 12.83
2nd Resistance Point 12.50
1st Resistance Point 12.05
Last Price 11.59
1st Support Level 11.27
2nd Support Level 10.94
3rd Support Level 10.49

See More

52-Week High 13.43
Last Price 11.59
Fibonacci 61.8% 10.47
Fibonacci 50% 9.56
Fibonacci 38.2% 8.64
52-Week Low 5.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar